These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2807626)

  • 21. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.
    van der Zee HH; de Ruiter L; van den Broecke DG; Dik WA; Laman JD; Prens EP
    Br J Dermatol; 2011 Jun; 164(6):1292-8. PubMed ID: 21332464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IFN-gamma prevents TNF-alpha-induced apoptosis in C2C12 myotubes through down-regulation of TNF-R2 and increased NF-kappaB activity.
    Tolosa L; Morlá M; Iglesias A; Busquets X; Lladó J; Olmos G
    Cell Signal; 2005 Nov; 17(11):1333-42. PubMed ID: 16125053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia.
    Gelin J; Moldawer LL; Lönnroth C; Sherry B; Chizzonite R; Lundholm K
    Cancer Res; 1991 Jan; 51(1):415-21. PubMed ID: 1703040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-gamma overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages.
    Luedke CE; Cerami A
    J Clin Invest; 1990 Oct; 86(4):1234-40. PubMed ID: 2120285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. YC-1 rescues cancer cachexia by affecting lipolysis and adipogenesis.
    Chung TH; Yen-Ping Kuo M; Chen JK; Huang DM
    Int J Cancer; 2011 Nov; 129(9):2274-83. PubMed ID: 21557215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cachectin activity in the serum of cachectic, tumor-bearing rats.
    Stovroff MC; Fraker DL; Norton JA
    Arch Surg; 1989 Jan; 124(1):94-9. PubMed ID: 2910253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers.
    Di Minno MN; Iervolino S; Peluso R; Russolillo A; Lupoli R; Scarpa R; Di Minno G; Tarantino G;
    J Rheumatol; 2012 May; 39(5):1042-6. PubMed ID: 22422493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor.
    Vlassara H; Moldawer L; Chan B
    J Clin Invest; 1989 Dec; 84(6):1813-20. PubMed ID: 2556447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Role of NF-kappa B in cancer cachexia].
    Zhou W; Jiang ZW; Jiang J; Li N; Li JS
    Zhonghua Wai Ke Za Zhi; 2004 Jun; 42(11):683-6. PubMed ID: 15329260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo.
    Siegel SA; Shealy DJ; Nakada MT; Le J; Woulfe DS; Probert L; Kollias G; Ghrayeb J; Vilcek J; Daddona PE
    Cytokine; 1995 Jan; 7(1):15-25. PubMed ID: 7538333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat.
    Stovroff MC; Fraker DL; Swedenborg JA; Norton JA
    Cancer Res; 1988 Aug; 48(16):4567-72. PubMed ID: 3165053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cachectin: a hormone that triggers acute shock and chronic cachexia.
    Tracey KJ; Lowry SF; Cerami A
    J Infect Dis; 1988 Mar; 157(3):413-20. PubMed ID: 3278061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purification and further characterization of a non-tumor necrosis factor alpha or beta differentiation-inducing cytokine, P48.
    Leftwich JA; Hall RE
    Cancer Res; 1989 Aug; 49(16):4459-65. PubMed ID: 2663142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of iron in the cytotoxicity of tumor necrosis factor.
    Warren S; Torti SV; Torti FM
    Lymphokine Cytokine Res; 1993 Apr; 12(2):75-80. PubMed ID: 8324080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human immunodeficiency virus-1 infection of macrophages in vitro neither induces tumor necrosis factor (TNF)/cachectin gene expression nor alters TNF/cachectin induction by lipopolysaccharide.
    Munis JR; Richman DD; Kornbluth RS
    J Clin Invest; 1990 Feb; 85(2):591-6. PubMed ID: 2298923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiological responses to cachectin.
    Tracey KJ; Lowry SF; Cerami A
    Ciba Found Symp; 1987; 131():88-108. PubMed ID: 2836140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potentiation of lymphokine-induced macrophage activation by tumor necrosis factor-alpha.
    Heidenreich S; Weyers M; Gong JH; Sprenger H; Nain M; Gemsa D
    J Immunol; 1988 Mar; 140(5):1511-8. PubMed ID: 3126228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
    Habtemariam S
    J Nat Prod; 1997 Aug; 60(8):775-8. PubMed ID: 9287415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mechanism and treatment of cancer cachexia in tumor-bearing mice].
    Li T; Li C
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):188-91. PubMed ID: 10920893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of enhancing antibodies on TNF interactions with its specific receptor: consequences for in vitro TNF antiviral activity.
    Lidbury BA; Rathjen DA; Ramshaw IA; Cowden WB
    Biotechnol Ther; 1994; 5(1-2):27-45. PubMed ID: 7703831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.